Axalimogene filolisbac
- Generic Name
- Axalimogene filolisbac
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- NY7PTD1862
- Background
Axalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Advaxis, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02399813
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Fox Chase, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath